Bortezomib + Isatuximab + Iberdomide + Lenalidomide + Dexamethasone

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Newly Diagnosed Multiple Myeloma

Conditions

Newly Diagnosed Multiple Myeloma

Trial Timeline

Oct 1, 2022 → Apr 1, 2029

NCT ID

NCT05558319

About Bortezomib + Isatuximab + Iberdomide + Lenalidomide + Dexamethasone

Bortezomib + Isatuximab + Iberdomide + Lenalidomide + Dexamethasone is a phase 3 stage product being developed by Bristol Myers Squibb for Newly Diagnosed Multiple Myeloma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05558319. Target conditions include Newly Diagnosed Multiple Myeloma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05558319	Phase 3	Recruiting	Oct 1, 2022	Apr 1, 2029	Newly Diagnosed Multiple Myeloma

Competing Products

18 competing products in Newly Diagnosed Multiple Myeloma

See all competitors

Product	Company	Stage	Hype Score
PLX3397 + Temozolomide	Daiichi Sankyo	Phase 1/2	41
Gliadel Wafer + Temozolomide	Eisai	Phase 2	52
Olaparib 300mg tablets	AstraZeneca	Phase 3	77
Pembrolizumab	Merck	Phase 2	52
Drug (including placebo)	Merck	Phase 1	33
Cilengitide	Merck	Phase 2	52
[177Lu]Lu-NeoB + [68Ga]Ga-NeoB	Novartis	Phase 1	33
BKM120 + Trastuzumab + Paclitaxel + BKM120 Placebo	Novartis	Phase 2	52
Tecentriq 1200 MG in 20 ML Injection + H3K27M peptide vaccine	Roche	Phase 1	33
Zenapax	Roche	Phase 2	52
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen	Amgen	Phase 3	76
Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + Dexamethasone	Pfizer	Phase 3	76
Elranatamab + Daratumumab + Lenalidomide	Pfizer	Phase 2	51
Lenalidomide + Dexamethasone + Elotuzumab	Bristol Myers Squibb	Phase 3	76
Isatuximab-Irfc 20 MG/ML [Sarclisa] + Lenalidomide + Dexamethasone Oral	Sanofi	Phase 2	51
Mebendazole	Brain Biotech	Phase 1	25
Balstilimab + Botensilimab + Liposomal Doxorubicin	Agenus	Phase 2	44
HLA-A2 restricted glioma antigen peptides vaccine + Poly-ICLC	Brain Biotech	Phase 1	25

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved